Operating Segments (Tables)

12 Months Ended

Dec. 31, 2019

Disclosure of operating segments [abstract]

Schedule of segment reporting information by segment

	For the year ended December 31, 2019
	Pain and Hypertension		Oncology		Total reportable segments		Reconciliations (*)		Total consolidated
	USD in thousands
Revenues		1,000		-		1,000		-		1,000
Research and development expenses		395		2,041		2,436		238		2,674
Operating loss		3,068		2,815		5,883		1,273		7,156
Finance income, net										(1,479	)
Tax Expenses										216
Loss for the year										5,893

	For the year ended December 31, 2018
	Pain and Hypertension		Oncology		Total reportable segments		Reconciliations (*)			Total consolidated
	USD in thousands
Revenues		1,000		-		1,000		-			1,000
Research and development expenses		2,185		2,537		4,722		546			5,268
Operating loss		4,730		3,217		7,947		(121	)		7,826
Finance income, net											(2,257	)
Loss for the year											5,569

	For the year ended December 31, 2017
	Pain and Hypertension		Oncology		Total reportable segments		Reconciliations (*)		Total consolidated
	USD in thousands
Revenues		100		-		100		-		100
Research and development expenses		2,603		1,328		3,931		709		4,640
Operating loss		6,674		1,951		8,625		3,341		11,966
Finance income, net										947
Loss for the year										12,913

(*) Includes employees share based expenses and other expenses/income related to rights granted to Taoz.